Christopher Longo has more than 20 years of industry experience in clinical research, economic evaluation, and market access strategies for pharmaceuticals. He has published both clinical and economic research in a number of therapeutic areas including diabetes, cancer, sepsis and central nervous system disorders. His primary program of research investigates efficiency and equity issues in health care by using health economics tools to address policy questions. Much of this work has been in chronic and critical illness, and involves collaboration with researchers who have appropriate clinical expertise. He has undertaken research projects examining pharmaceutical innovation and pricing, and issues related to equity of access within this industry. His current research focus examines the costs and economic evaluation of cancer programs and interventions throughout the cancer journey, with the intent of informing policy decision-making. Longo has consulted with numerous provincial and federal agencies related to economic evaluation of pharmaceuticals including: the Canadian Agency for Drugs and Technology in Health, Cancer Care Ontario, Ontario Ministry of Health and Long Term Care and the National Cancer Institute of Canada. Longo was the past chair of Rx&D’s (Canada’s Research-based Pharmaceutical Companies) Health Economic Working Group from 2002-2004. Longo also acted as an expert advisor to a number of Rx&D committees from 1997 to 2005. He has undertaken reviews for the journals Pharacoeconomics, Medical Care, Canadian Medical Association Journal, Value in Health, Journal of Palliative Care, European Journal of Cancer Care and Supportive Care in Cancer.